Are there any concerns or precautions clinicians should be aware of when switching a patient from IV daratumumab to subcutaneous?

FAQ Library published on April 11, 2022
Download Transcript
Saad Z. Usmani, MD, FACP
Chief of Myeloma Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

That's a very good question. I think if someone has previously been on IV Dara, it's a good idea to go back and see if they had an infusion-related reaction. If they had a reaction, was it just mild (Grade 1-2) or not? If they had no reaction to the IV formulation and they're getting SQ formulation, it's okay to watch those patients for maybe an hour before letting them go home. I think we've experienced this in our clinical practices and see this quite frequently.

For someone who did have a higher grade infusion-related reaction with IV formulation, even though the product is the same, I think the first time patients are getting it, it may be worthwhile keeping that patient around a little bit longer, but no longer than four hours.

Last modified: April 4, 2022